Renaissance Capital logo

Alumis Priced, Nasdaq: ALMS

Phase 3-ready biotech developing kinase inhibitors for immune-mediated diseases.

Industry: Health Care

Latest Trade: $12.50 0.00 (0.0%)

First Day Return: -16.9%

Return from IPO: -21.9%

Industry: Health Care

We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule. ESK-001 has demonstrated significant therapeutic effect in our Phase 2 program in patients with PsO, which we define as moderate-to-severe plaque psoriasis (PsO), and is currently being evaluated in additional Phase 2 clinical trials in patients with systemic lupus erythematosus (SLE) and non-infectious uveitis (Uveitis), for which we expect to report results in 2026 and by the end of 2024, respectively. With the favorable results in our Phase 2 clinical trial in PsO, we intend to initiate multiple Phase 3 clinical trials of ESK-001 in the second half of 2024 in this indication. TYK2 genetic mutations are associated with a strong protective effect in multiple sclerosis, motivating us to develop our second product candidate, A-005, as a CNS-penetrant, allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. In April 2024, we initiated our Phase 1 program of A-005 in healthy volunteers and expect to report initial results by the end of 2024.
more less
IPO Data
IPO File Date 06/07/2024
Offer Price $16.00
Price Range $16.00 - $18.00
Offer Shares (mm) 13.1
Deal Size ($mm) $210
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 06/27/2024
Offer Price $16.00
Price Range $16.00 - $18.00
Offer Shares (mm) 13.1
Deal Size ($mm) $210
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
Morgan Stanley
Leerink Partners
more
Company Data
Headquarters South San Francisco, CA, United States
Founded 2021
Employees 109
Website www.alumis.com

Alumis (ALMS) Performance